What’s the current market cap for Oxford Nanopore Technologies stock?

Oxford Nanopore Technologies (ONT) has a market cap of £1.3B as of May 26, 2026.

What is the P/E ratio for Oxford Nanopore Technologies stock?

The price to earnings (P/E) ratio for Oxford Nanopore Technologies (ONT) stock is 0 as of May 26, 2026.

Does Oxford Nanopore Technologies stock pay dividends?

No, Oxford Nanopore Technologies (ONT) stock does not pay dividends to its shareholders as of May 26, 2026.

When is the next Oxford Nanopore Technologies dividend payment date?

Oxford Nanopore Technologies (ONT) stock does not pay dividends to its shareholders.

What is the beta indicator for Oxford Nanopore Technologies ?

Oxford Nanopore Technologies (ONT) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Oxford Nanopore Technologies stock | £ONT Share Price

07:00

09:10

11:15

13:25

15:30

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc, trading under the ticker ONT, operates in the biotechnology sector, focusing on the development of nanopore technology for DNA and RNA sequencing. Founded in 2005 and publicly listed, the company's innovative technology facilitates real-time, scalable, and accessible biological research, with applications ranging from healthcare to environmental science. Based in the UK, Oxford Nanopore has revolutionized the approach to molecular analysis by providing a direct and electric characterization of single molecules.

Ticker

£ONT

Sector

Health

Primary listing

LSE

Employees

1,316

Headquarters

Oxford, United Kingdom

Website

nanoporetech.com

ONT Metrics

BasicAdvanced

£1.3bn

-£0.15

0.87

What the Analysts think about ONT

Analyst ratings (Buy, Hold, Sell) for Oxford Nanopore Technologies stock.

Bulls say / Bears say

Revenue grew 24.2% on a constant currency basis to £223.9 million in FY2025, slightly ahead of the top end of guidance, driven by broad-based growth across all regions and customer segments, including Clinical (+59.9%), BioPharma (+30.4%), Applied Industrial (+27.2%) and Research (+15.1%).

Shares jumped over 6% after full-year revenue came in slightly above guidance, led by approximately 40% year-on-year growth in the PromethION platform driven by clinical demand.

Entered a new strategic partnership with Cepheid to develop and commercialise automated infectious disease sequencing solutions, enhancing its clinical diagnostics offering.

Lowered its medium-term revenue growth target for 2026 to 21–25%, causing shares to fall nearly 13% on concerns about slowing growth once several strategic research projects conclude before new ones begin.

Reported a one-off £22.6 million of restructuring costs in FY2025 to realign strategic focus, weighing on reported profitability despite improved operating performance.

The core MinION product range grew just 2.4% year-on-year in FY2025, suggesting potential saturation in its portable sequencing business.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

ONT Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ONT Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by London Stock Exchange, through Infront.

Buy £ONT

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Shares jumped over 6% after full-year revenue came in slightly above guidance, led by approximately 40% year-on-year growth in the PromethION platform driven by clinical demand.

Entered a new strategic partnership with Cepheid to develop and commercialise automated infectious disease sequencing solutions, enhancing its clinical diagnostics offering.

Reported a one-off £22.6 million of restructuring costs in FY2025 to realign strategic focus, weighing on reported profitability despite improved operating performance.

The core MinION product range grew just 2.4% year-on-year in FY2025, suggesting potential saturation in its portable sequencing business.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

About Oxford Nanopore Technologies

Ticker

Primary listing

Employees

ONT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ONT

Analyst Ratings

Bulls say / Bears say

ONT Financial Performance

Income Statement

ONT Earnings Performance

Earnings per share (EPS)

Buy £ONT

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Oxford Nanopore Technologies /£ONT

About Oxford Nanopore Technologies

Ticker

Primary listing

Employees

ONT Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about ONT

Analyst Ratings

Bulls say / Bears say

ONT Financial Performance

Income Statement

ONT Earnings Performance

Earnings per share (EPS)

Buy £ONT

Upcoming events

No upcoming events

What’s the current market cap for Oxford Nanopore Technologies stock?

What is the P/E ratio for Oxford Nanopore Technologies stock?

Does Oxford Nanopore Technologies stock pay dividends?

When is the next Oxford Nanopore Technologies dividend payment date?

What is the beta indicator for Oxford Nanopore Technologies ?

Bulls say / Bears say